Abstract:Protein misfolding and aggregation are cardinal features of neurodegenerative disease (NDD) and they contribute to pathophysiology by both loss-of-function (LOF) and gain-of-function (GOF) mechanisms. This is well exemplified by TDP-43 which aggregates and mislocalizes in several NDDs. The depletion of nuclear TDP-43 leads to reduction in its normal function in RNA metabolism and the cytoplasmic accumulation of TDP-43 leads to aberrant protein homeostasis. A modifier screen found that loss of suppressed TDP-43 pathology in invertebrate and tissue culture models. Here we show in a mouse model of TDP-43 pathology that genetic or antisense oligonucleotide (ASO)-mediated reduction in confers benefits on survival and behavior, histological hallmarks of disease and reduction of mislocalized and aggregated TDP-43. This results in improved function of the ubiquitin-proteasome system (UPS) and correction of transcriptomic alterations evoked by pathologic TDP-43. RAD23A-dependent remodeling of the insoluble proteome appears to be a key event driving pathology in this model. As TDP-43 pathology is prevalent in both familial and sporadic NDD, targeting may have therapeutic potential.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether reducing the RAD23A protein can prolong lifespan and alleviate pathological manifestations in mouse models of TDP - 43 pathology. Specifically, researchers reduced the expression of RAD23A through gene knockdown or using antisense oligonucleotide (ASO) technology and observed its impact on mice (TAR4/4 mice) carrying the human wild - type TDP - 43 (hTDP - 43) transgene. These impacts include the prolongation of survival, behavioral improvement, changes in histological features, and the reduction of mislocalized and aggregated TDP - 43. In addition, the study also explored the molecular mechanisms behind these changes, especially the role of RAD23A in regulating the protein homeostasis network and its relationship with TDP - 43 pathology. ### Main Findings 1. **Prolonged Survival**: The reduction of RAD23A significantly prolonged the survival of TAR4/4 mice, with male and female mice having an increased lifespan of approximately 7 days and 10 days respectively. 2. **Pathological Improvement**: After the reduction of RAD23A, phenotypes such as movement disorders, tremors, and hunchbacks in mice were alleviated. 3. **Neuronal Protection**: The thickness of the motor cortex increased, the neuronal density improved, and astrocyte proliferation decreased in TAR4/4;RAD23AKD mice. 4. **Changes in TDP - 43 Levels and Localization**: The reduction of RAD23A led to a decrease in the total expression of hTDP - 43, an increase in the nucleocytoplasmic ratio, and a decrease in sarkosyl - insoluble TDP - 43. 5. **Improvement of Protein Homeostasis**: The reduction of RAD23A improved the function of the ubiquitin - proteasome system, reduced the accumulation of ubiquitinated proteins, and decreased the levels of p62 and total ubiquitin. 6. **Transcriptome Changes**: The reduction of RAD23A reversed many gene expression changes caused by TDP - 43 pathology, especially genes related to nerve function, neural development, mitochondrial function, and autophagy. ### Molecular Mechanisms - **Interaction between TDP - 43 and RAD23A**: Although the reduction of RAD23A improved TDP - 43 pathology, experimental results showed that there was no direct physical interaction between RAD23A and TDP - 43. This indicates that RAD23A may affect the aggregation and degradation of TDP - 43 in an indirect way. - **Proteasome Function**: The reduction of RAD23A reduced the accumulation of proteasomes in the sarkosyl - insoluble fraction and restored the activity of proteasomes, thereby improving protein homeostasis. In conclusion, this study reveals the important role of RAD23A in TDP - 43 pathology and provides new ideas for the development of treatment strategies for TDP - 43 - related neurodegenerative diseases.

Reduction of RAD23A extends lifespan and mitigates pathology in TDP-43 mice

Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice

Sustained Therapeutic Benefits by Transient Reduction of TDP-43 Using ENA-modified Antisense Oligonucleotides in ALS/FTD Mice

RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy

ASO-enhancement of exitron splicing mitigates TDP-43 proteinopathies

Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis models

O‐GlcNAcylation of TDP‐43 suppresses proteinopathies and promotes TDP‐43’s mRNA splicing activity

A transient protein folding response targets aggregation in the early phase of TDP-43-mediated neurodegeneration

A TDP-43 acetylation-mimic mutation that disrupts RNA-binding drives FTLD-like neurodegeneration in a mouse model of sporadic TDP-43 proteinopathy

Short RNA chaperones promote aggregation-resistant TDP-43 conformers to mitigate neurodegeneration

Transcriptome-based screening in TARDBP/TDP-43 knock-in motor neurons identifies the NEDD8-activating enzyme inhibitor MLN4924

Endogenous TDP-43 mislocalization in a novel knock-in mouse model reveals DNA repair impairment, inflammation, and neuronal senescence

TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanisms

Reduced STMN2 and pathogenic TDP-43, two hallmarks of ALS, synergize to accelerate motor decline in mice

TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition

DDX3X overexpression decreases dipeptide repeat proteins in a mouse model of C9ORF72-ALS/FTD

Single Acetylation-mimetic Mutation in TDP-43 Nuclear Localization Signal Disrupts Importin α1/β Signaling

Identification of genetic modifiers of TDP-43 neurotoxicity in Drosophila

TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43

TDP-43 dysregulation of polyadenylation site selection is a defining feature of RNA misprocessing in ALS/FTD and related disorders

CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis